Drs. Keith Kerr and Sanja Dacic shared findings from the IASLC Pathology Committee, which is investigating how to best assess pathologic response to neoadjuvant immunotherapy in lung cancer. Read more
During WCLC 2023, Dr. Yan Zhang presented findings that she says support the inclusion of factors such as early menarche and early menopause in lung cancer screening programs. Read more
Drs. Wendy Cooper, Melissa Culligan, And Navneet Singh concluded the session with talks on the future of pathology, enhancing the patient experience, and accurate staging in lung cancer. Read more
The challenge, Step It Up for Research, helped WCLC 23 attendees stay active during the meeting while raising money to support the IASLC Foundation, which provides grants for research, education, and other scientific initiatives. Read more
Drs. Silvia Novello, Alan Sihoe, and D. Ross Camidge kicked off the session with forward-looking talks on tobacco control and smoking cessation, surgery, and medical oncology. Read more
After more than 2 years, the median duration of response was 12.4 months and no new safety signals were seen, according to Dr. Shirish Gadgeel, who presented the results during WCLC 2023. Read more
Dr. Solange Peters presented new follow-up data from CheckMate 227 that show positive results regardless of PD-L1 expression. Read more
During WCLC 2023, researcher Dr. Kevin Lamote shared data that demonstrated VOCs in exhaled breath could be a useful biomarker. Read more
IASLC leaders also shared highlights from the association’s membership growth and financial report and officially welcomed President Dr. Paul Van Schil. Read more
Drs. Keith Kerr and Sanja Dacic will examine the role of pathology in patient selection and specimen interpretation in the era of neoadjuvant immunotherapy. Read more